Mibefradil dihydrochloride, Ca2+ channel blocker (ab120343)

Submit a review Submit a question References (4)

Key features and details

  • Ca2+ channel blocker
  • CAS Number: 116666-63-8
  • Purity: > 98%
  • Soluble in water to 50 mM
  • Form / State: Solid
  • Source: Synthetic

Overview

  • Product name

    Mibefradil dihydrochloride, Ca2+ channel blocker

  • Description

    Ca2+ channel blocker

  • Biological description

    Ca2+ channel blocker. Shows moderate selectivity for T-type channels (IC50 values are 2.7 and 18.6 μM for T-type and L-type respectively). Shows antihypertensive effects in vivo. Orally active.

  • Purity

    > 98%

  • CAS Number

    116666-63-8

  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate dihydrochloride

  • Molecular weight

    568.56

  • Molecular formula

    C29H38FN3O3.2HCl

  • Storage instructions

    Store at Room Temperature. Store under desiccating conditions. The product can be stored for up to 12 months.

  • Solubility overview

    Soluble in water to 50 mM

  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    Cl.Cl.CC(C)[C@H]4c5ccc(F)cc5CC[C@]4(OC(=O)C1CC1)CCN(C)CCCc2nc3ccccc3n2

  • Source

    Synthetic

  • Research areas

Protocols

To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

Click here to view the general protocols

References (4)

Publishing research using ab120343? Please let us know so that we can cite the reference in this datasheet.

ab120343 has been referenced in 4 publications.

  • Cerina M  et al. Thalamic Kv 7 channels: pharmacological properties and activity control during noxious signal processing. Br J Pharmacol 172:3126-40 (2015). PubMed: 25684311
  • Bancila M  et al. Two structurally different T-type Ca 2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats. Fundam Clin Pharmacol 25:469-78 (2011). PubMed: 21039820
  • Major TC  et al. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay. J Pharmacol Exp Ther 325:723-31 (2008). PubMed: 18326812
  • Clozel JP  et al. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl 15:S17-25 (1997). PubMed: 9481612

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab120343.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com